Suppr超能文献

阿根廷人群中视神经脊髓炎谱系障碍患者的死亡率:来自RelevarEM注册研究。

Mortality of neuromyelitis optica spectrum disorder patients in an Argentinean population: A study from the RelevarEM registry.

作者信息

Carnero Contentti Edgar, Lopez Pablo A, Pettinicchi Juan Pablo, Criniti Juan, Pappolla Agustín, Miguez Jimena, Cristiano Edgardo, Patrucco Liliana, Liwacki Susana, Tkachuk Verónica, Balbuena María E, Vrech Carlos, Deri Norma, Correale Jorge, Marrodan Mariano, Ysrraelit María C, Leguizamon Felisa, Luetic Geraldine, Menichini María L, Tavolini Darío, Mainella Carolina, Zanga Gisela, Burgos Marcos, Hryb Javier, Barboza Andrés, Lazaro Luciana, Alonso Ricardo, Fernández Liguori Nora, Nadur Débora, Alonso Serena Marina, Caride Alejandro, Paul Friedemann, Rojas Juan I

机构信息

Neuroimmunology Unit, Department of Neurosciences, Hospital Alemán, Buenos Aires, Argentina.

Servicio de Neurología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

出版信息

Mult Scler J Exp Transl Clin. 2023 Oct 17;9(4):20552173231205444. doi: 10.1177/20552173231205444. eCollection 2023 Oct-Dec.

Abstract

We aimed to evaluate mortality and causes of death among Argentinean neuromyelitis optica spectrum disorder (NMOSD) patients and identify predictors of death. Retrospective study included 158 NMOSD patients and 11 (7%) patients died after 11 years of follow-up for a total exposure time of 53,345 days with an overall incidence density of 2.06 × 10.000 patients/day (95% CI 1.75-2.68). Extensive cervical myelitis with respiratory failure (45%) was the most frequent cause of death. Older age (HR = 2.05,  = 0.002) and higher disability score (HR = 2.30,  < 0.001) at disease onset were independent predictors of death. We found an 11-year mortality rate of 7% in Argentinean NMOSD patients.

摘要

我们旨在评估阿根廷视神经脊髓炎谱系障碍(NMOSD)患者的死亡率和死亡原因,并确定死亡的预测因素。回顾性研究纳入了158例NMOSD患者,11例(7%)患者在11年的随访后死亡,总暴露时间为53345天,总体发病密度为2.06×10000患者/天(95%CI 1.75-2.68)。伴有呼吸衰竭的广泛性颈髓炎(45%)是最常见的死亡原因。发病时年龄较大(HR = 2.05,P = 0.002)和残疾评分较高(HR = 2.30,P < 0.001)是死亡的独立预测因素。我们发现阿根廷NMOSD患者的11年死亡率为7%。

相似文献

1
Mortality of neuromyelitis optica spectrum disorder patients in an Argentinean population: A study from the RelevarEM registry.
Mult Scler J Exp Transl Clin. 2023 Oct 17;9(4):20552173231205444. doi: 10.1177/20552173231205444. eCollection 2023 Oct-Dec.
4
Mortality of neuromyelitis optica spectrum disorders in a Chinese population.
Ann Clin Transl Neurol. 2021 Jul;8(7):1471-1479. doi: 10.1002/acn3.51404. Epub 2021 Jun 13.
5
Clinical and radiological profile of neuromyelitis optica spectrum disorders in a Pakistani cohort.
Mult Scler Relat Disord. 2023 Jun;74:104656. doi: 10.1016/j.msard.2023.104656. Epub 2023 Mar 24.
6
Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice.
Neurol Ther. 2021 Dec;10(2):767-783. doi: 10.1007/s40120-021-00253-4. Epub 2021 May 27.
7
Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
Mult Scler. 2017 Nov;23(13):1748-1756. doi: 10.1177/1352458516685416. Epub 2017 Jan 6.
8
Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
Mult Scler. 2014 Jul;20(8):1086-94. doi: 10.1177/1352458513515085. Epub 2013 Dec 9.
9
What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM).
Mult Scler Relat Disord. 2021 Apr;49:102742. doi: 10.1016/j.msard.2021.102742. Epub 2021 Jan 7.
10
Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Qatar Med J. 2022 Jul 7;2022(3):29. doi: 10.5339/qmj.2022.29. eCollection 2022.

引用本文的文献

1
A structured approach for identifying disease analogs for pulmonary arterial hypertension.
J Manag Care Spec Pharm. 2025 Sep;31(9):909-921. doi: 10.18553/jmcp.2025.24354. Epub 2025 Jul 31.
2
Therapeutic inertia in the management of neuromyelitis optica spectrum disorder.
Front Neurol. 2024 Feb 21;15:1341473. doi: 10.3389/fneur.2024.1341473. eCollection 2024.

本文引用的文献

1
Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
J Neuroinflammation. 2021 Sep 16;18(1):208. doi: 10.1186/s12974-021-02249-1.
2
Mortality of neuromyelitis optica spectrum disorders in a Chinese population.
Ann Clin Transl Neurol. 2021 Jul;8(7):1471-1479. doi: 10.1002/acn3.51404. Epub 2021 Jun 13.
3
Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study.
Neurology. 2019 Jul 9;93(2):e181-e189. doi: 10.1212/WNL.0000000000007746. Epub 2019 Jun 6.
4
The Argentinean multiple sclerosis registry (RelevarEM): Methodological aspects and directions.
Mult Scler Relat Disord. 2019 Jul;32:133-137. doi: 10.1016/j.msard.2019.05.004. Epub 2019 May 15.
5
Mortality in neuromyelitis optica is strongly associated with African ancestry.
Neurol Neuroimmunol Neuroinflamm. 2018 Jun 7;5(4):e468. doi: 10.1212/NXI.0000000000000468. eCollection 2018 Jul.
6
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. Epub 2015 Jun 19.
7
Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
Mult Scler. 2014 Jul;20(8):1086-94. doi: 10.1177/1352458513515085. Epub 2013 Dec 9.
9
Relapsing neuromyelitis optica: long term history and clinical predictors of death.
J Neurol Neurosurg Psychiatry. 2009 Oct;80(10):1162-4. doi: 10.1136/jnnp.2007.143529.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验